Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer

Lin, Ying‐Li; Li, Yanli; Ma, Jun

doi:10.12659/msm.904366

Cited by 16 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21,22 Recent studies showed that PCDH8, PCDH10 and PCDH17 acted as tumor suppressors in a variety of human cancers. [23][24][25][26][27][28][29][30][31][32][33][34] PCDH9 is another member of the PCDH family located in the 13q21.32 of human genome. Previous studies demonstrated that PCDH9 was down-regulated in cancers, such as glioblastoma, hepatocellular carcinoma and gastric cancer.…”

Section: Introductionmentioning

confidence: 99%

<p>MiR-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9</p>

Shi¹,

Yang²,

Zhang³

et al. 2019

OTT

View full text Add to dashboard Cite

Background: Increasing evidence has revealed that the aberrant expression of microRNAs (miRNAs) plays vital roles in the development and progression of ovarian cancer. MiR-200a-3p was found to act as an oncogene in a variety of cancers, however, the expression and function of miR-200a-3p in ovarian cancer has not been characterized. Materials and methods: The expression of miR-200a-3p in ovarian cancer tissues and cell lines was detected by the RT-qPCR. The influence of miR-200a-3p on the growth of ovarian cancer cells was determined with the Cell Counting Kit-8 assay, colony formation and cell invasion assay. The binding of miR-200a-3p with the 3ʹ-untranslated region (UTR) of PDCH9 was detected by luciferase reporter assay. The expression of PCDH9 was investigated by RT-qPCR and Western blot analysis. Results: miR-200a-3p was up-regulated in ovarian cancer tissues and cell lines. Highly expressed miR-200a-3p was significantly associated with the tumor size, tumor metastasis and TNM stage. Overexpression of miR-200a-3p markedly promoted the proliferation, colony formation and invasion of ovarian cancer cells. Functional study uncovered that miR-200a-3p bound the 3ʹ-untranslated region (UTR) of PCDH9 and decreased the expression of PCDH9 in ovarian cancer cells. The expression of miR-200a-3p in ovarian cancer tissues was significantly negatively correlated with that of PCDH9. Restored PCDH9 inhibited the promoting effect of miR-200a-3p on the proliferation of ovarian cancer cells. Conclusion: Our results suggested the potential oncogenic function of miR-200a-3p via modulating PCDH9 in ovarian cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>MiR-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9</p>

Shi¹,

Yang²,

Zhang³

et al. 2019

OTT

View full text Add to dashboard Cite

show abstract

“…In another study, cfDNA methylation of the APC, GSTP1, RASSFI, MDRI and PTGS2 genes was associated with overall survival time in men with advanced PCa [60]. Additionally, MSP on a cohort of n = 117 patient serum samples showed that PCDH8 methylation was an independent predictive risk factor for BCR-free survival (p< 0.007) in low GS (< 7) PCa patients after surgery [169]. Overall, these studies highlight the potential value of DNA methylation biomarkers in cfDNA as prognostic indicators of relapse.…”

Section: Blood-based Methylated Prognostic Biomarkers For Cfdna Testingmentioning

confidence: 94%

Advances in Prognostic Methylation Biomarkers for Prostate Cancer

Lam

Clark

Stirzaker

et al. 2020

Preprint

View full text Add to dashboard Cite

There is a major clinical need for accurate biomarkers for prostate cancer prognosis, to better inform treatment strategies and disease monitoring. Current clinically recognised prognostic factors, including prostate-specific antigen (PSA) levels, lack sensitivity and specificity in distinguishing aggressive from indolent disease, particularly in patients with localised intermediate grade prostate cancer. There has therefore been a major focus on identifying molecular biomarkers that can add prognostic value to existing markers, including investigation of DNA methylation, which has a known role in tumorigenesis. In this review, we will provide a comprehensive overview of the current state of DNA methylation biomarker studies in prostate cancer prognosis, and highlight the advances that have been made in this field. We cover the numerous studies into well-established candidate genes, and explore the technological transition that has enabled hypothesis-free genome-wide studies and the subsequent discovery of novel prognostic genes.

show abstract

“…Patients in the same stage all received the same standard treatment. Peripheral blood samples (10 ml) were collected within one week before surgery, and centrifuged at 1800 g for 10 min [18]. Sera were collected and stored at -80 °C until analysis.…”

Section: Methodsmentioning

confidence: 99%

“…DNA extraction, bisulfite conversion and methylation specific PCR (MSP). DNA was extracted from sera of patients according to the instructions of the QIAmp DNA Blood Mini Kit (Tiangen Biotech, China) [18], and the isolated DNA was modified by bisulfite using EZ DNA Methylation-Gold kit (Zymo Research, USA). MSP was used to detect the methylation status of T-cadherin in sera.…”

Section: Methodsmentioning

confidence: 99%

Aberrant promoter methylation of T-cadherin in sera is associated with a poor prognosis in oral squamous cell carcinoma

Wang¹,

Chen²,

Chen³

et al. 2021

neo

View full text Add to dashboard Cite

T-cadherin functions as a suppressor gene, which is frequently inactivated by aberrant promoter methylation in several human cancers, but its methylation status in oral squamous cell carcinoma (OSCC) has been scarcely studied. Thus this study aimed at exploring the clinical significance and prognostic value of T-cadherin methylation in sera of patients with OSCC. Methylation-specific PCR (MSP) and bisulfate sequencing PCR (BSP) was performed to examine the methylation status of T-cadherin. Then, the associations between methylation status of T-cadherin and various clinicopathological variables or patient survival were investigated in 202 patients with OSCC and 68 controls. T-cadherin methylation was detected in 62 out of 202 (30.7%) patients with OSCC, and the methylation status of T-cadherin in corresponding tissues was confirmed by BSP. Methylationof T-cadherin was significantly associated with advanced tumor T-stage (P < 0.001) and N-stage (P = 0.003), positive lymphatic metastasis (P = 0.004) and tumor recurrence (P = 0.001). In addition, patients with methylation of T-cadherin had worse overall survival (P = 0.018) and progression-free survival (P < 0.001) than patients without, and methylation of T-cadherin in sera was an independent prognostic factor for worse overall survival (HR: 3.626, 95%

show abstract

Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer

Cited by 16 publications

References 29 publications

<p>MiR-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9</p>

<p>MiR-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9</p>

Advances in Prognostic Methylation Biomarkers for Prostate Cancer

Aberrant promoter methylation of T-cadherin in sera is associated with a poor prognosis in oral squamous cell carcinoma

Contact Info

Product

Resources

About